ArticleNews reportPHN-05342026-11-01 22:37 CT
China leads Asia-Pacific obesity drug race as Korea pursues
Source · Chosunbiz
TLDR
China accounts for 21 of 30 Asia-Pacific obesity drug candidates, followed by South Korea with six, according to a KoreaBIO Association report cited by Chosunbiz. The article reports that regional companies are increasingly completing trials and launching drugs themselves rather than transferring development to overseas partners.
01—Key points
- 01KoreaBIO’s tally includes approved drugs and candidates in clinical trials; Japan accounts for two and India for one.
- 02Chosunbiz reports Chinese approval of Sciwind’s GLP-1 drug ecnoglutide and South Korean approval and launch of Hanmi Pharmaceutical’s eppe.
- 03Korean development programs include a triple-receptor candidate and a candidate intended to reduce weight while preserving muscle.
Why it matters Editorial
The association says competition in obesity drugs will increasingly depend on price and supply capacity as well as the amount of weight loss.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
No related news yet.